Healthcare Industry News: antibiotic
News Release - September 7, 2011
Rib-X Announces Senior Management PromotionsRib-X Announces Senior Management Promotions
NEW HAVEN, Conn.--(Healthcare Sales & Marketing Network)-- Rib-X Pharmaceuticals, Inc., a development-stage company with an industry leading pipeline of broad spectrum antibiotics, today announced the promotions of Erin Duffy, Ph.D., to Chief Scientific Officer and Jarrod Longcor to Vice President, Corporate Development.
"Rib-X has a number of programs advancing into late-stage clinical trials, an achievement that can be attributed wholly to the hard work and dedication of our team,” said Mark Leuchtenberger, President and Chief Executive Officer. “These appointments recognize the contributions of two key members and provide the opportunity to accelerate our growth in the next-stage of development. Erin is widely recognized by the scientific community for her deep insight into ribosomal structure and function, and has pioneered the rational design of novel antibiotics targeting the bacterial ribosome. The RX-04 program, which was recently partnered with Sanofi, was developed under her leadership and we are confident that Erin and her team will continue to deliver new, exciting programs from our powerful drug discovery engine.”
Leuchtenberger continued, “Jarrod is a highly accomplished business development executive and was the engineer behind our recent partnership with Sanofi. He has a strong track record of success in creating mutually beneficial and long-lasting collaborations. Jarrod’s expertise is ideally suited to lead Rib-X corporate development as we continue to receive interest in our discovery capabilities and our antibiotic pipeline moves into late-stage development and we look forward to his contributions.”
Erin Duffy, Ph.D., joined Rib-X early in 2002 and previously served as the Company’s Vice President of Discovery Research. She has over 20 years of research experience in chemistry, biology and related disciplines. Prior to joining Rib-X, Dr. Duffy was the Associate Director of Innovative Discovery Technologies at Achillion Pharmaceuticals, Inc. and, before that, spent five years as a computational chemist with Pfizer Global Research and Development in Groton, Connecticut. Dr. Duffy trained at Yale University, received her Ph.D. in physical-organic chemistry and moved to the Molecular Biophysics and Biochemistry Department for postdoctoral work.
Jared Longcor joined Rib-X in 2007 and previously served as Senior Director, Business Development. He has over 15 years of experience in the biopharmaceutical industry, combining research skill with 10 years of experience in business development. Prior to joining Rib-X, Mr. Longcor served as the Director of Business Development at MaxCyte, Inc., where he was responsible for developing regional partnerships. Prior to MaxCyte, he served as the Senior Director of Business Development for Advancis Pharmaceutical Corporation. In this role, he was responsible primarily for the establishment and management of multiple partnerships. Mr. Longcor received his MBA from St. Joseph’s Haub School of Business, a Masters of Medicine from Boston University School of Medicine and his B.S. from Dickinson College.
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals is developing broad spectrum antibiotics with superior coverage, safety and convenience to deliver new standards of care for patients with serious infections. The Company’s Nobel Prize winning platform enables a unique understanding of how antibiotics combat infection and has generated an industry leading pipeline spanning all phases of research and clinical development. www.rib-x.com
Source: Rib-X Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.